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We aimed to investigate transmission rates of pertus-
sis in household contacts of cases and factors associ-
ated with transmission. A prospective epidemiological 
study was conducted in 2012 and 2013 to determine 
the incidence of pertussis among household contacts 
of reported cases in Catalonia and Navarre, Spain. An 
epidemiological survey was completed for each case 
and contact, who were followed for 28 days to deter-
mine the source of infection (primary case) and detect 
the occurrence of secondary cases. Odds ratios (ORs) 
were used to estimate the effectiveness of vaccination 
and chemoprophylaxis in preventing new cases, using 
the formula (1 − OR) × 100. For the 688 primary cases, 
a total of 2,852 contacts were recorded. The house-
hold transmission rate was 16.1% (459/2,852) and rose 
according to the age (> 18 years) and lack of immuni-
sation of the primary cases, and also the age (0–18 
years), family relationship (siblings and children), 
lack of vaccination and chemoprophylaxis of contacts. 
Pertussis vaccine effectiveness in preventing new 
cases was 65.0% (95% confidence interval (CI): 11.6 
to 86.2) for full vaccination (≥ 4 doses) and 59.7% (95% 
CI: −6.8 to 84.8) for incomplete vaccination (< 4 doses). 
The effectiveness of chemoprophylaxis was 62.1% 
(95% CI: 40.3 to 75.9). To reduce household transmis-
sion, contacts should be investigated to detect fur-
ther cases and to administer chemoprophylaxis. The 
current vaccination status of cases and contacts can 
reduce household transmission.
Introduction
Pertussis vaccination has led to an important reduction 
in the incidence of the disease in children in the past 
60 years [1]. However, pertussis remains a vaccine-pre-
ventable disease that causes a large number of deaths 
worldwide [2] and has high incidence and hospitalisa-
tion rates, even in industrialised countries [3,4].
Studies suggest that the persistence of transmission of 
the causative agent, Bordetella pertussis, is due to the 
fact that immunity to B. pertussis infection – whether 
acquired naturally or by vaccination – is not lifelong 
[5,6]. In fact, a second infection in people who have 
already been infected with B. pertussis have been 
reported [7]. When whole-cell vaccines (wPs) are used, 
protective antibodies decline by 50% over a period of 6 
to 12 years [5,8]. The duration of immunity conferred by 
acellular vaccines (aPs) – which are used today in most 
industrialised countries because they are less reacto-
genic [9] – appears to be shorter than that conferred 
by wP [10,11]. Some studies suggest that aPs induce a 
suboptimal immune response that is unable to prevent 
infection, thus providing a plausible explanation for 
pertussis resurgence [12].
In Spain, the wP against pertussis, combined with 
diphtheria and tetanus toxoids (DTwP), was commer-
cialised in the 1960s and was administered to infants 
(aged under 1 year) in two annual campaigns [13]. In 
Catalonia and Navarre, the wP was included in 1980 
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in the national childhood immunisation schedule, with 
four doses at 3, 5, 7 and 18 months of age. In 1998, the 
vaccination schedule was changed, reducing the age of 
administration and number of the wP doses at 2, 4 and 
6 months of age, and included two doses of the aP (at 
18 months and 4–6 years of age). In 2002, five doses of 
aP – diphtheria, tetanus and acellular pertussis (DTaP)/
combined tetanus, diphtheria and acellular pertussis 
(Tdap) – were introduced into the childhood immunisa-
tion schedule, with the last dose given at the age of 
4–6 years, to reduce the side effects of wP vaccination. 
In Spain, vaccination coverage with pertussis vaccines 
has been more than 90% since 1990 [13]. Nevertheless, 
pertussis incidence increased from less than 1 per 
100,000 population in 2003 to 5.3 per 100,000 popula-
tion in 2013 [13].
Studies of children worldwide hospitalised due to seri-
ous outcomes of pertussis have shown that the most 
frequent source of infection is in the household, due to 
infection by mothers or other family members (siblings, 
fathers, grandparents) or caregivers, who presented 
with symptoms of coughing that were not recognised 
as being due to pertussis [14-16].
Other studies of community index cases also indicate 
that B. pertussis transmission often occurs in house-
holds and that transmission rates in this setting are 
variable but high, depending on factors related to the 
pertussis cases and their contacts, such as age, sex or 
immune status [17,18].
The rate of secondary transmission of B. pertussis in 
Spanish households and the relative importance of 
family relationships and specific age groups regard-
ing infection is unknown. Similarly, chemoprophylaxis 
with azithromycin is recommended for post-exposure 
prophylaxis [19], but its effectiveness, and that of 
DTwP/DTaP/Tdap vaccination, in preventing transmis-
sion in household contacts is also unknown. Such 
data could be valuable in the assessment of strategies 
to reduce the number of B. pertussis infections, espe-
cially in children.
The aim of our study was to investigate the sources of 
infection of primary cases and rates of secondary trans-
mission of pertussis in contacts of pertussis cases in 
households and factors associated with transmission 
in Catalonia and Navarre, Spain.
Methods
A prospective epidemiological study was conducted 
in 2012 and 2013 on the incidence of pertussis 
among household contacts of pertussis cases who 
were reported to the notifiable diseases systems of 
Catalonia and Navarre, which together have a popula-
tion of 8.2 million [20].
Index cases (defined below) were reported to public 
health professionals from the epidemiological surveil-
lance units of the Department of Health of Catalonia, 
the Public Health Agency of Barcelona and the Public 
Health Institute of Navarre. Each case notified was con-
sidered an index case. To be included in the study, an 
individual had to meet the criteria for a confirmed case 
(see below) and have household contacts who could 
be identified.
For each index case detected, an epidemiological sur-
vey of the study variables (outlined below) was com-
pleted and household contacts were identified. Each 
case was asked about exposure to a person with per-
tussis, symptoms, doses of pertussis vaccine received 
(registered in an official document or medical history) 
and preventive measures adopted (vaccination or 
Table 1
Characteristics of primary cases of pertussis with 
household contacts, Catalonia and Navarre, Spain, 
2012–13 (n = 688)
Characteristic of primary case Number %
Sex 
Male 325 47.2
Female 363 52.8
Age in years 
< 1 151 21.9
1 24 3.5
2–3 44 6.4
4–6 76 11.0
7–10 149 21.7
11–18 98 14.2
19–40 76 11.0
> 40 70 10.2
Clinical symptoms 
Cough lasting > 2 weeks 644 93.6
Paroxysmal cough 581 84.4
Post-tussive vomiting 276 40.1
Inspiratory stridor 259 37.6
Apnoea 151 21.9
Fever 74 10.8
Laboratory confirmation (PCR and/or culture)
Yes 504 73.3
No 184 26.7
Hospitalisation 
Yes 105 15.3
No 583 84.7
Vaccination statusa
Fully vaccinated 331 48.1
Undervaccinated due to age 90 13.1
Undervaccinated 15 2.2
Unvaccinated 61 8.9
Unvaccinated due to age 66 9.6
Unknown/no answer 125 18.2
a Vaccination status was categorised as fully vaccinated (≥ 4 doses 
of vaccine), undervaccinated (< 4 doses), unvaccinated (no dose), 
undervaccinated due to age (< 4 doses) and unvaccinated due to 
age (no dose).
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chemoprophylaxis). As the transmission period of the 
disease may be as long as 21 days [21] and the incuba-
tion period in a new case seven days [22], cases and 
contacts were followed for 28 days to determine the 
source of infection (primary case), and the appearance 
of secondary cases.
Two samples were taken, using appropriate swabs 
(Dacron or Rayon for PCR) and cotton for cultures), 
from the posterior nasopharynx of each case and con-
tact with pertussis-compatible symptoms for determin-
ing presence of B. pertussis by culture or PCR. Swabs 
for culture were transported in a suitable medium to 
ensure viability of the bacteria and swabs for PCR were 
resuspended in 200 µL saline solution. B. pertussis 
DNA was detected using real-time PCR amplification of 
the insertion sequences Bordetella IS481 [23]. Human 
RnaseP gene was used to check sample quality and 
detection of inhibitors of PCR reaction.
Definitions
An index case was defined as the first reported per-
tussis case who generated the study of pertussis in a 
particular household. 
A confirmed case was defined as a person present-
ing clinically with a cough, together with microbiologi-
cal confirmation (isolation of B. pertussis in culture 
or positive PCR test from nasopharyngeal swabs) or a 
person who fulfilled the clinical definition (cough for 
more than two weeks and at least one of the follow-
ing: paroxysmal cough, inspiratory stridor, post-tussive 
vomiting or apnoea) and who was also epidemiologi-
cally linked to a confirmed case.
A primary case was defined as the first confirmed case 
of pertussis in a household to develop symptoms. 
A coprimary case was defined a confirmed case of per-
tussis with symptoms appearing between 0 and 6 days 
after those of the primary case had started. 
A secondary case was a confirmed case in whom symp-
toms began between 7 and 28 days after those of the 
primary case. 
After completion of the survey and laboratory tests, 
each index case and household contact was classi-
fied as a healthy contact, primary case or secondary 
case (confirmed microbiologically or by epidemiologi-
cal link).
Household contacts were defined as all residents of 
the household of the primary case (cohabitants) or 
persons who had had contact with the primary case 
for more than 2 hours (to exclude sporadic contact) in 
the same dwelling during the transmission period of 
the disease (non-cohabitants) in order to detect cases 
among relatives and caregivers who were not house-
hold cohabitants but could have a relevant role in the 
epidemiological chain. We choose 2 hours to eliminate 
sporadic contact (with less than 2 hours of contact).
The transmission period of the disease was defined as 
the period of 21 days from the onset of symptoms in 
the primary case or five days from the onset of treat-
ment of the primary case. 
Table 2
Characteristics of household contacts of primary cases 
of pertussis, Catalonia and Navarre, Spain, 2012–13 
(n = 2,852)
Characteristic of household contact Number %
Sex 
Male 1,340 47.0
Female 1,512 53.0
Age in years
< 1 150 5.3
1 58 2.0
2–3 132 4.6
4–6 200 7.0
7–10 221 7.7
11–18 209 7.3
19–40 967 33.9
> 40 915 32.1
Household contacts 
Cohabitant 2,034 71.3
Non-cohabitant 818 28.7
Relationship to primary case 
Mother 556 19.5
Father 510 17.9
Sibling 518 18.2
Grandparent 330 11.6
Child 139 4.9
Partner 100 3.5
Othera 699 24.5
Number of contacts in the household 
≤ 2 226 7.9
3–4 1,133 29.7
> 4 1,493 52.3
Vaccination status (≤ 18 years)b
Fully vaccinated 581 64.4
Undervaccinated due to age 94 10.4
Undervaccinated 27 3.0
Unvaccinated 49 5.4
Unvaccinated due to age 53 5.9
Unknown/no answer 97 10.8
Received chemoprophylaxisc
Yes 2,284 80.1
No 406 14.2
Unknown 162 5.7
a Caregiver, family friend or neighbour.
b Vaccination status was categorised as fully vaccinated (≥ 4 doses 
of vaccine), undervaccinated (< 4 doses), unvaccinated (no dose), 
undervaccinated due to age (< 4 doses) and unvaccinated due to 
age (no dose).
C Azithromycin was used.
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Study variables
Information on the following sets of variables was 
obtained from a face-to-face questionnaire and official 
records for each pertussis case and each household 
contact.
Demographic variables: sex, age, number of persons 
in a household (cohabitant or non-cohabitant) and 
the relationship between the household members. For 
contacts, the relationship with the primary case (e.g. 
mother, father, sibling, grandparent, child, partner, 
other) was recorded.
Clinical variables: date of onset of first symptom, 
cough lasting 2 or more weeks, number of days of per-
sistent cough, and presence/absence of paroxysmal 
coughing, post-tussive vomiting, apnoea, fever, pneu-
monia, seizures, encephalopathy, hospitalisation.
Laboratory results: type of sample, result of culture 
and PCR.
Preventive measures: for study participants – all cases 
of pertussis (all ages) and household contacts (aged 
≤ 18 years) – who had received any dose of pertus-
sis vaccine, the number and date of administration of 
doses were recorded. The cut-off of 18 years was cho-
sen because few contacts aged more than 18 years had 
records of their vaccinations. Vaccination status was 
categorised as fully vaccinated (≥ 4 doses of vaccine), 
undervaccinated (< 4 doses), unvaccinated (no dose), 
undervaccinated due to age (< 4 doses) and unvacci-
nated due to age (no dose). 
Chemoprophylaxis was defined as completion of anti-
biotic treatment (azithromycin) in a healthy contact 
(all ages) initiated after symptom onset of the primary 
case.
Sample size
Given that the annual median number of new cases 
in Catalonia and Navarre was 203 [24] and the study 
Table 3
Incidence of pertussis in household contacts by characteristic of primary cases (n = 2,852)
Characteristic of  
primary case
Incidence of pertussis  
among contacts Odds ratio 95% CI
% n/total
Sex
Female 16.0 245/1,528 1.0 0.8 to 1.2
Male 16.2 214/1,324 Reference
Age in years
< 1 8.9 60/671 Reference
1 9.6 10/104 1.1 0.5 to 2.2
2–3 10.9 25/229 1.2 0.7 to 2.0
4–6 14.4 47/326 1.7 1.1 to 2.6
7–10 15.3 91/595 1.8 1.3 to 2.6
11–18 14.9 54/363 1.8 1.2 to 2.6
19–40 31.0 90/290 4.6 3.2 to 6.6
> 40 29.9 82/274 4.3 3.0 to 6.3
Microbiological confirmation (PCR and/or culture)
Yes 10.7 219/2,055 Reference
No 27.0 61/226 3.1 2.2 to 4.3
Unknown 30.8 158/513 3.7 2.9 to 4.7
Hospitalisation
Yes 10.0 48/479 0.6 0.4 to 0.8
No 17.4 403/2,312 Reference
Number of contacts
≤ 2 19.5 44/226 Reference
3–4 16.0 181/1,133 0.8 0.6 to 1.1
> 4 15.7 234/1,493 0.8 0.6 to 1.1
Vaccination statusa
Fully vaccinated 14.1 188/1,331 Reference
Undervaccinated/ Unvaccinated/Unknown 17.8 271/1,521 1.3 1.1 to 1.6
CI: confidence interval.
a Vaccination status was categorised as fully vaccinated (≥ 4 doses of vaccine), undervaccinated (< 4 doses) or unvaccinated (no dose).
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period was 2 years, we expected to register 406 new 
cases during the study. Taking a mean of three house-
hold contacts (excluding the index case), we expected 
to register 1,218 household contacts. The median size 
of families in Spain is 2.5 members [25]; however, as 
other contacts in households, such as caregivers, were 
included, we decided to use a mean of three. 
The rate of transmission in households, assuming an 
expected level of 10% [21], was estimated to a preci-
sion of ± 1.7%. 
Data analysis
Primary cases and contacts were described using per-
centages with their 95% confidence intervals (CIs) for 
qualitative variables, and means and standard devia-
tion (SD) for quantitative variables.
The rate of transmission with its 95% CI was calculated 
using the formula:
Primary cases were not included in the numerator or 
the denominator.
The risk of transmission was studied according to the 
characteristics of primary cases and their household 
contacts using the chi-squared test for qualitative vari-
ables and the ANOVA or Kruskall tests for quantitative 
variables, with a level of significance of p < 0.05. The 
strength of an association was calculated using odds 
ratios (ORs) and their 95% CIs.
The vaccine effectiveness (only in household contacts 
aged 18 years or under) and chemoprophylaxis (in all 
household contacts) was studied using the formula: 
Effectiveness = (1 − OR) × 100. The estimated ORs were 
adjusted using an unconditional logistic regression 
model produced by eliminating variables using step-
wise regression in which predictive variables were car-
ried out by the automatic backward method starting 
with all candidate variables and eliminating variables 
from p < 0.2. 
The variables evaluated in the models were vaccination 
status, use of chemoprophylaxis, age, sex and family 
relationship of the contacts, in addition to the sex, age 
and vaccination status of the primary case.
Ethical aspects
The study was approved by the Ethics Committee of 
the Hospital Sant Joan de Deu (code: PIC-79–11). All 
contacts and family members were informed about the 
study and gave their consent to participate.
Table 4
Incidence of pertussis in household contacts by 
characteristic, Catalonia and Navarre, Spain, 2012–13 
(n = 2,852)
Characteristic of 
household contact
Incidence of pertussis  
among contacts Odds 
ratio 95% CI
% n/total
Sex
Female 15.9 241/1,512 1.0 0.8 to 1.2
Male 16.3 218/1,340 Reference
Age in years
< 1 69.3 104/150 24.6 16.2 to 37.4
1 44.8 26/58 8.8 5.0 to 15.6
2–3 25.0 33/132 3.6 2.3 to 5.7
4–6 21.5 43/200 3.0 2.0 to 4.5
7–10 19.5 43/221 2.6 1.7 to 3.9
11–18 19.1 40/209 2.6 1.7 to 3.9
19–40 9.6 93/967 1.2 0.8 to 1.6
> 40 8.4 77/915 Reference
Household contacts
Cohabitants 16.5 336/2034 1.1 0.9 to 1.4
Non-cohabitants 15.0 123/818 Reference
Relationship with primary case
Mother 8.3 46/556 1.8 1.0 to 3.4
Father 8.8 45/510 2.0 1.1 to 3.7
Sibling 25.7 133/518 7.2 4.2 to 12.6
Grandparent 4.5 15/330 Reference
Child 61.2 85/139 33.0 17.7 to 61.5
Partner 16.0 16/100 4.0 1.9 to 8.4
Othera 17.0 119/699 4.3 2.5 to 7.5
Vaccination statusb (≤ 18 years)
Fully vaccinated 23.8 138/581 0.11 0.07 to 0.17
Undervaccinated 52.9 64/121 0.38 0.22 to 0.68
Unvaccinated 74.5 76/102 Reference
Received chemoprophylaxisc
Yes 9.9 226/2,284 0.47 0.35 to 0.62
No 19.0 77/406 Reference
CI: confidence interval.
a Caregiver, family friend or neighbour.
b Vaccination status was categorised as fully vaccinated (≥ 4 doses 
of vaccine), undervaccinated (< 4 doses) or unvaccinated (no 
dose).
c Azithromycin was used.
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Results
We studied 688 index cases, of whom 76.2% (524/688) 
were the primary cases in the household. The remain-
der (164/688) were secondary cases (household con-
tacts). Thus the 688 primary cases studied (the first 
cases who became symptomatic in a household) com-
prised 524 index cases and 164 household contacts 
who were identified as primary cases once the study of 
the household was complete. 
Of these 688 confirmed primary cases, 52.8% were 
female, 21.9% were aged under 1 year, 42.6% 1–10 
years, 14.2% 11–18 years and 21.2% more than 18 
years. Primary cases had the following symptoms: 
cough lasting more than 2 weeks (93.6%), paroxysmal 
cough (84.4%), post-tussive vomiting (40.1%), inspira-
tory stridor (37.6%), apnoea (21.9%) and fever (10.8%) 
(Table 1). The frequency of symptoms experienced by 
primary cases aged more than 18 years was slightly dif-
ferent: cough lasting more than 2 weeks (98.6%), par-
oxysmal cough (84.4%), post-tussive vomiting (23.1%), 
inspiratory stridor (30.6%), apnoea (20.4%) and fever 
(6.8%). Of the 688 primary cases, 15.3% were hospi-
talised, including 63.6% (96/151) of those aged under 1 
year.
Laboratory confirmation (PCR and/or culture) was 
obtained for 73.3% (n = 504) of the primary cases and 
by epidemiological link in 26.7% (n  =  184); 48.1% of 
cases were fully vaccinated (they had received ≥ 4 
doses of vaccine), 13.1% were undervaccinated due 
to age, 2.2% were simply undervaccinated, 8.9% had 
received no vaccine dose and 9.6% were unvaccinated 
due to age (Table 1).
A total of 2,852 household contacts of the 688 primary 
cases were recorded, of whom 52.8% were female, 
66.0% were older than 18 years, 7.3% were aged 11–18 
years and 26.6% were under 11 years. About 71% of the 
contacts were cohabitants, i.e. they lived in the same 
household as the primary case. The most common 
family relationships among the contacts were being a 
mother (19.5%), father (17.9%) or sibling (18.2%) of the 
primary case. Some 64% of contacts aged ≤ 18 years 
were fully vaccinated, 13% were undervaccinated and 
11% were unvaccinated (Table 2).
The household transmission rate (incidence of pertus-
sis among household contacts) was 16.1% (459/2,852) 
and was slightly higher when the primary case was 
male (16.2%), but this difference was not statistically 
significant. Compared with data from primary cases 
aged under 1 year, the household transmission rate was 
higher when the primary case was aged 4–6 years (OR: 
1.7; 95% CI: 1.1 to 2.6), 7–10 years (OR: 1.8; 95% CI: 1.3 
to 2.6), 11–18 years (OR: 1.8; 95% CI: 1.2 to 2.6), 19–40 
years (OR: 4.6; 95% CI: 3.2 to 6.6) and older than 40 
years (OR = 4.3; 95% CI: 3.0 to 6.3). It was also higher 
when the primary case was undervaccinated, unvacci-
nated or of unknown vaccination status (OR: 1.3; 95% 
CI: 1.1 to 1.6), when compared with primary cases who 
were fully vaccinated (Table 3). 
There was no statistically significant difference 
between the transmission rate in households with 2 or 
fewer contacts (19.5%), 3–4 contacts (16.0%) or more 
than 4 contacts (15.7%) (p > 0.05) (Table 3).
When looking at the transmission rate assessed 
according to variables of household contacts, the rate 
was slightly higher in male contacts (16.3%) than in 
female (15.9%), but this difference was not statistically 
significant. The rate was considerably higher in con-
tacts aged under 1 year (OR: 24.6; 95% CI: 16.2 to 37.4), 
1 year (OR: 8.8; 95% CI: 5.0 to 15.6), 2–3 years (OR: 3.6; 
95% CI: 2.3 to 5.7), 4–6 years (OR: 3.0; 95% CI: 2.0 to 
4.5), 7–10 years (OR: 2.6; 95% CI: 1.7 to 3.9) and 11–18 
years (OR = 2.6; 95% CI: 1.7–3.9), compared with those 
aged more than 40 years (Table 4). 
No difference in transmission rate was observed 
between contacts who were cohabitants and those who 
were non-cohabitants (with exposure for more than 2 
hours in the household of the primary case). However, 
the transmission rate was higher in siblings (OR: 7.2; 
95% CI: 4.2 to 12.6) and children (OR: 33.0; 95% CI: 17.7 
to 61.5) of primary cases (Table 4). 
Vaccine effectiveness in household contact aged ≤ 18 
years was 89% (95% CI: 83 to 93) in reducing transmis-
sion in contacts vaccinated with 4 or fewer doses and 
62% (95% CI: 32 to 78) in undervaccinated contacts. 
Chemoprophylaxis in all contacts had an effectiveness 
of 53% (95% CI: 38 to 65) in avoiding new cases.
Table 5
Multivariate analysis of the effectiveness of pertussis 
vaccination and chemoprophylaxis of household contacts 
in reducing household transmission, Catalonia and 
Navarre, Spain, 2012–13
Characteristic of  
household contact
Adjusted  
odds ratioa 95% CI p value
Vaccination statusb (≤ 18 years)
Fully vaccinated 0.350 0.138 to 0.884 0.026
Undervaccinated 0.403 0.152 to 1.068 0.067
Unvaccinated Reference –
Received chemoprophylaxisc
Yes 0.379 0.241 to 0.597 0.001
No Reference –
CI: confidence interval.
a Adjusted by age of contacts, sex of contacts, relationship with 
primary case, sex of primary case, age of primary case and 
pertussis vaccination status of primary case.
b Vaccination status was categorised as fully vaccinated (≥ 4 doses 
of vaccine), undervaccinated (< 4 doses) or unvaccinated (no 
dose).
C Azithromycin was used.
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In the multivariate analysis, the effect of vaccination 
and chemoprophylaxis for contacts in avoiding new 
cases was still seen. Vaccine effectiveness in reduc-
ing transmission in contacts aged ≤ 18 years was 65.0% 
(95% CI: 11.6 to 86.2) for full vaccination and 59.7% 
(95% CI: −6.8 to 84.8%) for undervaccinated contacts. 
The adjusted effectiveness of chemoprophylaxis, 
based on adjusted ORs (Table 5), in all contacts was 
62.1% (95% CI: 40.3 to 75.9).
Discussion
The results of this study show that the rate of house-
hold transmission of pertussis in Spain in 2012 and 
2013 was high, especially in contacts aged under 18 
years, siblings and children of a primary case, unvac-
cinated contacts and those who had not received 
chemoprophylaxis.
Household transmission of pertussis is known to be 
related to the characteristics of primary cases and 
their contacts [26]. We found increased transmission 
in households of primary cases aged 18–40 years 
and those older than 40 years. In the age group 18–40 
years, this could be due to closer contact between chil-
dren and the primary case, especially mothers, due 
to dependence [15,27]. For primary cases aged more 
than 40 years, the increased rate of transmission might 
be due to atypical clinical presentation, possibly result-
ing in important diagnostic delays and therefore more 
opportunities for transmission [16,27]. Lack of vac-
cination or undervaccination of the primary case also 
resulted in an increased transmission rate, as observed 
in other studies [28,29], showing that although full vac-
cination may not avoid the disease for some cases, it 
may reduce transmission from the primary case.
In our study, 35.4% of primary cases were adoles-
cents (11–18 year-olds) or adults (>  18 years). Other 
studies also suggest that adolescents and adults are 
an important reservoir of the pathogen and source 
of transmission to children, who are more vulnerable 
to infection and susceptible to serious complications 
[28]. In a report published in 1995, Wirsing von König 
et al. studied pertussis cases in 122 homes in 1995 in 
an area of Germany with very low vaccination coverage 
and estimated that adults were the source of infec-
tion in 15% of cases [18]. Later, Baptista et al. stud-
ied pertussis cases in 57 homes in Recife, Brazil, in 
2003 and found that adults were the primary source of 
infection in 21.1% of cases [21,30]. Deen et al. studied 
39 homes and 255 exposed persons in Los Angeles, 
United States, in 1995: in 53% of households, the pri-
mary case was aged older than 12 years [31]. Sala-Farré 
et al. investigated 59 clusters in an area of Barcelona 
in 2011 and found that the most frequent primary cases 
were children aged 5–9 years (29%), followed by adults 
aged 30–39 years (22%) [32].
In Catalan children in 2001 hospitalised due to severe 
symptoms of pertussis [33], the source of infection was 
determined for 63% of cases and for 44.6% of those 
whose infection source was determined, the source 
was an adolescent or adult. It is recognised that ado-
lescents and adults may act as a source of infection 
of children [14], but in these age groups the disease 
is often not diagnosed and is generally under-detected 
[34]. In a study in Massachusetts, United States, in 
1981 to 1991 Marchant et al. [23,35] found an increase 
in the incidence of confirmed cases in adolescents 
aged 11–19 years from 3 per 100,000 population to 12.9 
per 100,000 population, after facilitating general prac-
titioners’ access to serological diagnoses. In another 
study in Catalonia in 2013, the prevalence of B. per-
tussis infection in the previous 12 months was 1.8% in 
women of childbearing age (15–49 years), which sug-
gests there is potentially a high risk for newborns [36].
Studies in various countries that included children 
hospitalised due to severe disease have shown that 
the most frequent sources of infection were mothers 
or other family members (fathers, teenage siblings and 
grandparents) who presented with coughing that had 
not been recognised as due to pertussis [16,21,27,37].
The rate of familial transmission from primary cases 
has been estimated in some studies. In the 1990s, 
Wirsing von König et al. found a high transmission rate 
of 26.7% in adult household contacts in an area of 
Germany with very low vaccination coverage [18] and in 
2003, in Brazil, Baptista et al. found a rate of second-
ary transmission of 12.6% in adult household contacts 
[30].
In our study, we observed no differences between the 
number of contacts and transmission rate in the house-
hold. Similarly, in the study of Wirsing von König et 
al. the overall attack rate in adult contacts was inde-
pendent of the family size [18] but an ecological study 
from 2009–13 in Minnesota, United States, reported a 
greater rate of pertussis in counties with a larger aver-
age household size [38].
The main characteristics of contacts with an increased 
transmission rate in our study were being 0–18 years 
of age, the sibling or child of a primary case, not vacci-
nated or undervaccinated and not receiving chemopro-
phylaxis. In terms of age, we observed a reduction of 
transmission in the 11–18-year age group and in adults 
compared with that of the other age groups. This may be 
due to vaccination with wP, as suggested by the World 
Health Organization (WHO) position paper on pertus-
sis vaccines [9]. Reduced transmission in household 
adults was observed in the study of Baptista et al. in 
Recife, Brazil, in 2003. Some 87% of adults exposed to 
pertussis in the household did not acquire the disease: 
this was attributed to naturally acquired immunity [30]. 
In Catalonia and Navarre, five doses of aP were intro-
duced into the official vaccination schedule in 2002 
and therefore it may be assumed that most children 
aged under 11 years in our study were vaccinated with 
the aP. Specific responses to these changes, such as 
an adolescent booster dose (after the dose given at 
31www.eurosurveillance.org
age 4–6 years) and additional booster doses in adults, 
may be required. 
Pertussis has re-emerged as an important public health 
concern in Europe since the current aP replaced the 
older wP. Warfel et al. showed that non-human primates 
receiving aP were protected from severe symptoms but 
not infection, and readily transmitted B. pertussis to 
contacts [39]. Key differences in T-cell memory sug-
gest that aP vaccination induces a suboptimal immune 
response that is unable to prevent infection and pro-
vide a plausible explanation for pertussis resurgence 
[39]. Various studies suggest that attaining herd immu-
nity will require the development of improved vaccina-
tion strategies that prevent B. pertussis colonisation 
and transmission [34,39,40]. 
The increased risk of transmission to siblings of primary 
cases seen in our study has also been observed by oth-
ers [27,41]. The adjusted vaccine effectiveness of 65% 
in avoiding new cases in household contacts aged ≤ 18 
years is similar to or higher than that observed in other 
studies [42]. Sheridan et al. found an effectiveness 
of 53% or 64%, depending on the method of calcula-
tion used [43]. However, a position paper by the World 
Health Organization (WHO) [9] and a systematic review 
published in the Cochrane database [44] suggest the 
effectiveness is somewhat higher: 84–85% in prevent-
ing typical whooping cough and 71–78% in preventing 
mild pertussis disease. The effectiveness of chemo-
prophylaxis with azithromycin in our study in prevent-
ing transmission was high (62.1%), suggesting that the 
detection of pertussis cases, analysing their contacts, 
and chemoprophylaxis may reduce household trans-
mission, as has been suggested by others [21]. The 
evidence for the effectiveness of chemoprophylaxis in 
reducing transmission in household contacts is weak 
and based on expert opinion [45,46]. The results of our 
study and a recent cost–utility analysis [47] support 
the use of chemoprophylaxis in household contacts.
Our study has some limitations. First, it was based 
on notified cases of pertussis, which are known to be 
underdetected [35]. However, on the basis of the selec-
tion of study cases (confirmed cases with household 
contacts), an active search for contacts with pertus-
sis symptoms was carried out using the survey and 
the taking of samples from all symptomatic household 
contacts of primary cases. To ensure all cases were 
detected, contacts were followed for 28 days from con-
firmation of the index case. Nevertheless, there may 
have been transmission due to asymptomatic cases 
beyond the 28 days of follow-up and the incidence of 
pertussis may be underestimated. We may not have 
identified individuals in a household who had recently 
been infected but may not have reported any specific 
symptoms. Thus, what is measured and presented in 
this study is the effectiveness of preventing clinically 
notifiable disease and not the prevention of infection. 
Second, vaccination status was collected by docu-
mented evidence of vaccination in an official document 
or medical records: some patients could have been 
classified as unvaccinated due to vaccination not 
being recorded, but if such a mistake applies equally 
to household contacts who remain healthy and those 
who become pertussis cases, it should not alter the 
estimated vaccine effectiveness. Third, chemoprophy-
laxis was recommended to all contacts without symp-
toms after detection of the index case. Some contacts 
who received chemoprophylaxis might appear as cases 
due to continuous exposure to other cases of pertussis 
in the household and, therefore, the effectiveness of 
chemoprophylaxis may be underestimated. However, 
our estimate was obtained after having followed rou-
tine pertussis control practices and may be a good 
estimate of the expected effectiveness when chemo-
prophylaxis is prescribed by public health services.
In conclusion, the results of our study suggest that in 
order to reduce household transmission household 
contacts should be investigated to detect secondary 
cases and administer chemoprophylaxis rapidly. All 
contacts who have not received the correct number of 
doses of pertussis vaccine according to the vaccination 
schedule should be vaccinated, in addition to receiv-
ing chemoprophylaxis. The incidence rate was lower in 
fully vaccinated individuals and therefore cases could 
be avoided in the future, although not the immediate 
future, as pertussis vaccine is not effective as post-
exposure prophylaxis [47]. The previous pertussis 
vaccination status of cases and contacts is important 
in reducing the rate of household transmission. The 
administration of an additional dose of vaccine in ado-
lescents and adults (especially those in contact with 
children) could also help to reduce the transmission 
rate [42]. Nevertheless, there is now increasing evi-
dence that protection following booster doses of aP 
vaccines wanes faster in individuals primed with aP 
rather than with wP vaccines [9,34,39,40]. Such vacci-
nation programmes have an impact in directly targeted 
populations, but there is as yet no substantial evidence 
that they have had an important impact on severe per-
tussis in infants. Thus, WHO recommends that national 
programmes consider vaccinating pregnant women 
with one dose of Tdap (in the second or third trimester 
and preferably at least 15 days before the end of the 
pregnancy) in addition to routine primary infant pertus-
sis vaccination [9]. Ongoing surveillance of pertussis 
will be critical to monitor the changing epidemiology as 
the first ‘all-aP’-primed cohorts reach adulthood.
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